v3.25.4
INTANGIBLE ASSETS
12 Months Ended
Oct. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS

NOTE 5 – INTANGIBLE ASSETS

 

The following table sets forth the carrying amounts of intangible assets and goodwill including accumulated amortization as of October 31, 2025:

  

  

Remaining

Useful Life

  Cost   Impairment  

Accumulated

Amortization

  

Net Carrying

Value

 
Trademarks and tradenames  10.75 years  $693,330   $(418,512)  $(129,646)  $145,172 
Patents, know-how and unpatented technology  10.75 years   710,060    (388,259)   (139,365)   182,436 
Customer relationships  0 years   114,536    (17,108)   (97,428)   - 
Total     $1,517,926   $(823,879)  $(366,439)  $327,608 

 

  

Remaining

Useful Life

   Cost   Impairment  

Net Carrying

Value

 
Goodwill  Indefinite   $4,523,040   $(1,351,459)  $3,171,581 

 

The following table sets forth the carrying amounts of intangible assets and goodwill including accumulated amortization as of October 31, 2024:

 

  

Remaining

Useful Life

  Cost   Impairment  

Accumulated

Amortization

  

Net Carrying

Value

 
Trademarks and tradenames  11.75 years  $693,330   $(418,512)  $(116,142)  $158,676 
Patents, know-how and unpatented technology  11.75 years   710,060    (388,259)   (122,393)   199,408 
Customer relationships  0 years   114,536    (17,108)   (97,428)   - 
Total      1,517,926   $(823,879)  $(335,963)  $358,084 

 

  

Remaining

Useful Life

   Cost   Impairment  

Net Carrying

Value

 
Goodwill  Indefinite   $4,523,040   $(1,351,459)  $3,171,581 

 

 

The table below presents anticipated future amortization expense related to the Company’s intangible assets for each of the succeeding five fiscal years ending October 31;

  

      
2026  $30,475 
2027   30,475 
2028   30,475 
2029   30,475 
2030   30,475 
Thereafter   175,233 
Total  $327,608 

 

During the years ended October 31, 2025 and 2024, the Company recorded amortization expense of $30,476 and $63,702, respectively. The Company also recognized $0 and $49,431 of impairment expense related to its Fitore subsidiary during the years ending October 31, 2025 and 2024, respectively, and $0 and $196,595 of impairment expense related to its InfiniVive subsidiary during the year ended October 31, 2025 and 2024, respectively. In addition, the Company recorded impairment expense for the Goodwill of $437,368 during the year ended October 31, 2024 in its Fitore subsidiary due to lack of sales revenue. There was no impairment of Goodwill during the year ended October 31, 2025.